Open Access

What is considered cardiotoxicity of anthracyclines in animal studies

  • Authors:
    • Nikolaos Georgiadis
    • Konstantinos Tsarouhas
    • Ramin Rezaee
    • Haritini Nepka
    • George E.N. Kass
    • Jean‑Lou C.M. Dorne
    • Dimitrios Stagkos
    • Konstantinos Toutouzas
    • Demetrios A. Spandidos
    • Dimitrios Kouretas
    • Christina Tsitsimpikou
  • View Affiliations

  • Published online on: July 14, 2020     https://doi.org/10.3892/or.2020.7688
  • Pages: 798-818
  • Copyright: © Georgiadis et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Anthracyclines are commonly used anticancer drugs with well‑known and extensively studied cardiotoxic effects in humans. In the clinical setting guidelines for assessing cardiotoxicity are well‑established with important therapeutic implications. Cardiotoxicity in terms of impairment of cardiac function is largely diagnosed by echocardiography and based on objective metrics of cardiac function. Until this day, cardiotoxicity is not an endpoint in the current general toxicology and safety pharmacology preclinical studies, although other classes of drugs apart from anthracyclines, along with everyday chemicals have been shown to manifest cardiotoxic properties. Also, in the relevant literature there are not well‑established objective criteria or reference values in order to uniformly characterize cardiotoxic adverse effects in animal models. This in depth review focuses on the evaluation of two important echocardiographic indices, namely ejection fraction and fractional shortening, in the literature concerning anthracycline administration to rats as the reference laboratory animal model. The analysis of the gathered data gives promising results and solid prospects for both, defining anthracycline cardiotoxicity objective values and delineating the guidelines for assessing cardiotoxicity as a separate hazard class in animal preclinical studies for regulatory purposes.

Related Articles

Journal Cover

September-2020
Volume 44 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Georgiadis N, Tsarouhas K, Rezaee R, Nepka H, Kass GE, Dorne JLC, Stagkos D, Toutouzas K, Spandidos DA, Kouretas D, Kouretas D, et al: What is considered cardiotoxicity of anthracyclines in animal studies. Oncol Rep 44: 798-818, 2020
APA
Georgiadis, N., Tsarouhas, K., Rezaee, R., Nepka, H., Kass, G.E., Dorne, J.C. ... Tsitsimpikou, C. (2020). What is considered cardiotoxicity of anthracyclines in animal studies. Oncology Reports, 44, 798-818. https://doi.org/10.3892/or.2020.7688
MLA
Georgiadis, N., Tsarouhas, K., Rezaee, R., Nepka, H., Kass, G. E., Dorne, J. C., Stagkos, D., Toutouzas, K., Spandidos, D. A., Kouretas, D., Tsitsimpikou, C."What is considered cardiotoxicity of anthracyclines in animal studies". Oncology Reports 44.3 (2020): 798-818.
Chicago
Georgiadis, N., Tsarouhas, K., Rezaee, R., Nepka, H., Kass, G. E., Dorne, J. C., Stagkos, D., Toutouzas, K., Spandidos, D. A., Kouretas, D., Tsitsimpikou, C."What is considered cardiotoxicity of anthracyclines in animal studies". Oncology Reports 44, no. 3 (2020): 798-818. https://doi.org/10.3892/or.2020.7688